NCT06421259

Brief Summary

In order to assess the risk of hepatitis B reactivation in people living with HIV and undergoing injection therapy, we propose to carry out a descriptive analysis of the evolution of hepatitis B markers in this population.

Trial Health

43
At Risk

Trial Health Score

Automated assessment based on enrollment pace, timeline, and geographic reach

Trial has exceeded expected completion date
Enrollment
15

participants targeted

Target at below P25 for all trials

Timeline
Completed

Started May 2024

Geographic Reach
1 country

1 active site

Status
not yet recruiting

Health score is calculated from publicly available data and should be used for screening purposes only.

Trial Relationships

Click on a node to explore related trials.

Study Timeline

Key milestones and dates

First Submitted

Initial submission to the registry

May 13, 2024

Completed
7 days until next milestone

First Posted

Study publicly available on registry

May 20, 2024

Completed
Same day until next milestone

Study Start

First participant enrolled

May 20, 2024

Completed
2 years until next milestone

Primary Completion

Last participant's last visit for primary outcome

May 20, 2026

Completed
Same day until next milestone

Study Completion

Last participant's last visit for all outcomes

May 20, 2026

Completed
Last Updated

May 20, 2024

Status Verified

March 1, 2024

Enrollment Period

2 years

First QC Date

May 13, 2024

Last Update Submit

May 15, 2024

Conditions

Outcome Measures

Primary Outcomes (1)

  • Risk of HBV reactivation under injectable HIV ART

    HBV serology, DNA HBV levels

    From start of injectable HIV treatment to hepatitis B reactivation, assessed up to 24 months

Study Arms (1)

HIV infected patients under injectable ART

HIV infected patients under injectable ART

Eligibility Criteria

Age18 Years+
Sexall
Healthy VolunteersNo
Age GroupsAdult (18-64), Older Adult (65+)
Sampling MethodNon-Probability Sample
Study Population

HIV infected patients attending care in the infectiious disease department of the Universitary Hospital of Nice

You may qualify if:

  • HIV infected patients under injectable ART

You may not qualify if:

  • Active HBV infection

Contact the study team to confirm eligibility.

Sponsors & Collaborators

Study Sites (1)

CHU NiICE

Nice, Alpes Maritimes, 0600, France

Location

MeSH Terms

Conditions

HIV InfectionsHepatitis B

Condition Hierarchy (Ancestors)

Blood-Borne InfectionsCommunicable DiseasesInfectionsSexually Transmitted Diseases, ViralSexually Transmitted DiseasesLentivirus InfectionsRetroviridae InfectionsRNA Virus InfectionsVirus DiseasesGenital DiseasesUrogenital DiseasesImmunologic Deficiency SyndromesImmune System DiseasesHepadnaviridae InfectionsDNA Virus InfectionsHepatitis, Viral, HumanHepatitisLiver DiseasesDigestive System Diseases

Study Officials

  • Alissa NAQVI

    Centre Hospitalier Universitaire de Nice

    PRINCIPAL INVESTIGATOR

Central Study Contacts

Alissa NAQVI

CONTACT

Study Design

Study Type
observational
Observational Model
COHORT
Time Perspective
RETROSPECTIVE
Sponsor Type
OTHER
Responsible Party
SPONSOR

Study Record Dates

First Submitted

May 13, 2024

First Posted

May 20, 2024

Study Start

May 20, 2024

Primary Completion

May 20, 2026

Study Completion

May 20, 2026

Last Updated

May 20, 2024

Record last verified: 2024-03

Locations